Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Outcomes of Patients with LAL+ in At Least One Eye
Sponsor: Frank A. Bucci, Jr., M.D.
Summary
The objective of this study is to collect data on bilateral pseudophakic patients implanted with the RxSight Light Adjustable Lens+ (LAL+) in at least one eye
Official title: CLINICAL OUTCOMES of BILATERAL PSEUDOPHAKIC PATIENTS with a LIGHT ADJUSTABLE LENS+ (LAL)+ IMPLANTED in AT LEAST ONE EYE
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
25
Start Date
2024-10-16
Completion Date
2025-02-01
Last Updated
2024-10-21
Healthy Volunteers
No
Conditions
Interventions
Light Adjustable Lens+
The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
Locations (1)
Bucci Laser Vision Institute
Wilkes-Barre, Pennsylvania, United States